Scotia Capital Inc. Makes New $1.75 Million Investment in Cencora, Inc. (NYSE:COR)

Scotia Capital Inc. acquired a new position in shares of Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 7,786 shares of the company's stock, valued at approximately $1,749,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Boston Partners boosted its stake in shares of Cencora by 2.6% during the fourth quarter. Boston Partners now owns 5,007,100 shares of the company's stock valued at $1,128,058,000 after acquiring an additional 125,611 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Cencora by 3.1% in the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock valued at $969,471,000 after buying an additional 130,213 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Cencora by 20.4% during the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock valued at $728,757,000 after buying an additional 550,246 shares during the period. Pacer Advisors Inc. grew its stake in Cencora by 6.7% in the 4th quarter. Pacer Advisors Inc. now owns 2,204,242 shares of the company's stock worth $495,249,000 after acquiring an additional 138,868 shares during the period. Finally, Norges Bank acquired a new position in Cencora in the 4th quarter valued at $478,309,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Stock Up 0.9 %

NYSE COR traded up $2.58 during mid-day trading on Friday, reaching $287.02. 1,617,494 shares of the company's stock traded hands, compared to its average volume of 1,508,755. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $296.65. The company has a fifty day simple moving average of $263.20 and a 200-day simple moving average of $246.54. The company has a market cap of $55.66 billion, a price-to-earnings ratio of 40.83, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on COR shares. JPMorgan Chase & Co. increased their target price on Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday. StockNews.com upgraded Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Finally, Evercore ISI boosted their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $284.55.

Insider Buying and Selling at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. The trade was a 9.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the business's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,675 shares of company stock worth $8,034,778 over the last quarter. 10.80% of the stock is owned by corporate insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.